LIAISON® MDX
One instrument. Multiple discs. Ultimate Flexibility.
The supplier does not provide quotations for this product through SelectScience. You can search for similar products in our Product Directory.
Diasorin Liason DX is easy to use and provides reliable results.
Molecular infectious disease diagnosis
The Diasorin Liason MDX provides flexibility for the molecular detection of infectious disease agents in a user-friendly format. Direct specimen testing is available for a variety of targets in the convenient, easy to use 8 well disc format. Assay set up takes very little time and results are typically available in an hour. The instrument footprint is minimal and several instruments can be connected to a single laptop for assay programming and test execution. Master Mix is supplied in single-use vials, so there is no reagent waste. 8 well disc assays require only 2 pipetting steps, one for reagent and one for specimen, both the same volume. ASR assays are also available for a variety of targets and can be tested using the 96-well disc. Overall, the Diasorin Liason MDX provides flexibility in testing with a small footprint and user friendly format.
Review Date: 16 Nov 2018 | Diasorin Ltd
The LIAISON® MDX is an innovative and powerful thermocycler with two consumable disc options: the 8-well Direct Amplification Disc for sample-to-answer testing and the 96-well Universal Disc for higher volume testing.
Supported by an expanding menu of molecular assays, the LIAISON® MDX is flexible allowing you to run real-time PCR for qualitative, quantitative and multi-analyte detection. The instrument can perform both IVD as well as Laboratory Developed Tests.
The LIAISON® MDX software provides easy to understand results with the ability to check amplification curves after a run. The software also plots QC Charts and can be bi-directionally interfaced with LIS for easy integration into any lab workflow. You can also access and navigate the software during a run.
The instrument is also compact and expandable, with an extremely small footprint and the capability to connect up to four instruments with a single laptop.
510k clearance for Diasorin Simplexa COVID-19, Flu A/B, and RSV kit
The kit as broad coverage for influenza strains, emerging SARS-CoV-2 variants, and detection of both RSV subgroups A and B
Diasorin launches the Simplexa C. auris Direct assay on the LIASON MDX instrument in all countries accepting the CE mark
The assay is designed to improve infection control in healthcare settings through the rapid identification of patients suspected of Candida auris colonization
DiaSorin releases assay for rapid identification of SARS-CoV-2 variants
The Simplexa™ SARS-CoV-2 Variants Direct assay aims to enable detection of four mutations associated with virus variants without requiring upfront RNA extraction
DiaSorin launches LIAISON SARS-CoV-2 TrimericS IgG test for determination of IgG antibodies
The test could be used to assess antibody response against the native spike protein of SARS-CoV-2 following COVID-19 vaccination
DiaSorin's Simplexa COVID-19 direct molecular test CE marked for saliva specimens
The Direct assay is validated on a wide range of specimen types, and can be run in parallel with the Simplexa Flu A/B & RSV Direct Gen II assay
DiaSorin partners with MeMed to develop and commercialize diagnostics solution
Test to be integrated in over 5,000 DiaSorin analyzers, allowing physicians to differentiate between bacterial and viral infections
